Tetracycline Actions Relevant to Rosacea Treatment

H.C. Korting    C. Schöllmann

Department of Dermatology and Allergology, Ludwig-Maximilians-Universität, Munich, Germany

Key Words
Rosacea · Tetracyclines · Doxycycline · Inflammation · Matrix metalloproteinases · Cytokines · Reactive oxygen species · Angiogenesis

Abstract
Until today, the pathogenesis of rosacea is not known in detail. Yet in recent years evidence has been accumulating that rosacea with its common symptoms such as inflammatory lesions, erythema, telangiectasia, phymatous changes, and ocular symptoms is of inflammatory nature. Tetracycline derivatives like doxycycline successfully used in the treatment of skin diseases like acne and rosacea seem to inhibit different inflammatory pathways involved in the pathogenesis by various modes of action. Although data for skin diseases are relatively scanty, the following modes of action of tetracyclines seem to be most relevant for an effective treatment of acne and rosacea: inhibition of matrix metalloproteinases, downmodulation of cytokines, inhibition of cell movement and proliferation, inhibition of granuloma formation, inhibition of reactive oxygen species, nitric oxide, and angiogenesis, whereas inhibition of phospholipase A2 seems to be of lower importance. The role of the saprophytic mite *Demodex folliculorum* remains to be clarified. Additional studies are necessary to further elucidate how tetracyclines work in rosacea treatment.

Pathophysiology of Rosacea

Rosacea is a common chronic, often underdiagnosed, skin disease of uncertain etiology. The various clinical manifestations associated with this disease most frequently occur in the light-skinned Caucasian population, and in persons between 30 and 50 years of age [1, 2]. Until now the conventional wisdom has been that rosacea is more common in women than in men [2], whereas a recent analysis based on a cross-sectional study of rosacea (1995–2002) in 50,235 outpatients indicates that overall both sexes are equally affected by the disease [3]. The dermatological condition of rosacea mainly affects the cheek, nose, chin and central forehead. Furthermore, the disease may be linked to ocular manifestations [4]. The earliest symptoms associated with rosacea are intermittent, central facial flushing and erythema. More than 90% of the patients with rosacea experience flushing with episodes lasting up to 30 min occurring daily in more than 60% of the affected individuals [5–7]. With repetitive cycles, flushing becomes more prominent and facial redness deepens, in the end repeated episodes of facial flushing may cause persistent erythema and telangiectasia [8]. Many patients suffer from a stinging pain associated with episodes of flushing which can appear unpredictably or in relation to environmental, chemical, food or emotional triggers, especially exposure to sun [1].
Until today, the pathogenesis of rosacea is not known in detail. Yet in recent years evidence has been accumulating that rosacea is of inflammatory nature even though most data have their origin in diseases related to rosacea, namely acne vulgaris and, most commonly, periodontitis. For example, in biopsies of inflammatory lesions from patients with acne an increase in proinflammatory cytokines like tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) could be demonstrated [9]. These cytokines trigger a chain of reactions, such as the release of matrix metalloproteinases (MMPs), especially MMP-1, -3 and -9, involved in the degradation of extracellular matrix and inflammatory damage in turn supporting the development of papulopustular lesions [10, 11]. The fact that such lesions occur in rosacea as well supports the thesis of an inflammatory pathophysiology of this disease. Anyway, 2 further mediators of inflammation, reactive oxygen species (ROS) and nitric oxide (NO), have been shown to play a role in rosacea pathophysiology [12, 13]. It has in particular been shown that patients with severe rosacea have an impaired defense capacity against the proinflammatory and damaging effects of ROS [11, 14]. Reactive nitrogen intermediates like NO in turn are responsible for vasodilation possibly leading to increased vessel permeability and edema and supporting erythema and telangiectasia [11]. Flushing is caused by increased cutaneous blood flow because of capillary dilatations and is believed to be under vasomotor control [8]. It seems to arise from a dysregulation in the cutaneous vasomotor response, which, triggered by neurogenic, hormonal, thermal, topical or other stimuli, leads to an abnormal and persistent dilatation of blood vessels [15]. It is worth discussing that flushing – at least in the erythematotelangiectatic subtype of rosacea – may be due in part to an abnormal expression, function, distribution or responsiveness of α-adrenergic receptors [15].

A possible link between Helicobacter pylori infections and rosacea is discussed in the literature as well [11]. Several authors have also proposed that microscopic saprophytic mites – known as Demodex folliculorum – play a pathogenic role in papulopustular rosacea [16–21]. Mites increased in number may be involved in the pathogenesis of rosacea by provoking inflammatory or allergic reactions, by mechanical blockage of follicles or by acting as vectors for micro-organisms [17, 22]. It has been suggested that a density of D. folliculorum >5/cm² as determined with the standardized skin surface biopsy could be regarded as pathogenic [18], but other observations suggest that increased density of D. folliculorum, at least in peri-oral dermatitis, is a secondary phenomenon, associated with previous treatment with topical steroids [23].

Most recently it could be shown that symptoms of rosacea are exacerbated by factors that trigger innate immune responses, such as the release of cathelicidin antimicrobial peptides. These peptides are produced and secreted by keratinocytes [24]. Clearly, there is a role of cathelicidin in skin inflammatory responses [25], especially for cathelicidin LL-37 [24]. Individuals with rosacea express cathelicidin at abnormally high levels in their facial skin, and specific proteolytically processed forms of cathelicidin peptides found in rosacea differ from those in normal individuals [25]. This means that in the pathogenesis of rosacea, cathelicidin peptides are abnormally processed to forms that induce inflammation [26].

If changes in the skin pH play a role in pathophysiology, as it is reported for several skin diseases like irritant contact dermatitis, atopic dermatitis, ichthyosis or acne vulgaris [27], remains to be clarified.

In summary, there is good evidence that all the stigmata of rosacea are manifestations of an inflammatory process. It is highly probable that inflammatory pathways involved in the pathogenesis of this disease concomitantly contribute to the common complaints such as inflammatory lesions sensu stricto, erythema, telangiectasia, phymatous changes and ocular symptoms [28]. This view is supported by the fact that drugs like doxycycline successfully used in the treatment of rosacea inhibit various pathways of inflammation finally leading to an improvement of symptoms [9, 13, 29–31]. Furthermore, the anti-inflammatory properties of doxycycline strongly correspond to the pathophysiologic inflammatory mechanisms related to rosacea [31].

**Tetracyclines and Their Role in the Treatment of Rosacea**

Tetracyclines are broad-spectrum antibiotics that have been used in the treatment of rosacea for decades [9]. Treatment of papulopustular rosacea with tetracycline requires a 3- or 4-week regimen to achieve substantial improvement [32]. Tetracycline (250–1,000 mg per day), doxycycline (100–200 mg per day and – as demonstrated recently – also 20–40 mg per day) and minocycline (50–100 mg per day) are the most commonly applied compounds [33]. Until recently, the use of oral tetracyclines for rosacea was mainly based on clinical experience and a limited number of placebo-controlled studies [9, 34, 35].
However, most recent studies were carried out on the basis of a sufficiently large number of patients and can therefore be considered to be of high quality [31].

Today, the effectiveness of tetracyclines in skin diseases is considered to depend on their nonantibiotic actions, though originally developed as antibacterial drugs. Tetracyclines, besides acting as antibiotics, may also affect inflammation [31, 36], cell proliferation [37], apoptosis [38, 39] and angiogenesis [40] by variable mechanisms of action. In particular, it is the ability of tetracyclines to reduce the inflammatory response that significantly contributes to the clinical effectiveness for various indications like rosacea [30]. However, the observation that tetracyclines under ex vivo conditions augment the expression of cyclo-oxygenase-2 and increase prostaglandin E2 production [41] is not in line with the data described before because cyclo-oxygenase-2 and prostaglandin E2 activation are known to propagate inflammatory processes [42].

Today, second-generation tetracyclines, including minocycline and especially doxycycline, are most frequently and most successfully used in the treatment of rosacea. In comparison with their parent drug, the new generation of tetracyclines has an improved bioavailability, a longer elimination half-life and can be taken with food which minimizes gastrointestinal side effects [43]. A big advantage over the parent drug is that these substances are helpful for rosacea patients already at a subantimicrobial yet anti-inflammatory dose [31]. Thus, an effective and tolerable long-term therapy is feasible without running the risk of long-term antibiotics, i.e. undesired adverse effects such as gastrointestinal distress, candidal vulvovaginitis and/or the development of antibiotic-resistant micro-organisms [44].

Subantimicrobial-dose doxycycline is the only tetracycline approved in the USA for long-term use for up to 12 months [33]. The dosage of 20 mg of doxycycline hycdate twice daily or 40 mg once daily has been shown to be effective in the treatment of papulopustular rosacea with an excellent risk-benefit ratio. It has in particular been found that a 40-mg controlled-release formulation of doxycycline, applied once daily as Oracea™, conferred peak anti-inflammatory efficacy in the treatment of rosacea [45]. At subantimicrobial doses, long-term use of anti-inflammatory-dose doxycycline might not propagate bacterial resistance [33, 44, 46]. Two phase III, parallel-group, multicenter, randomized, double-blind, placebo-controlled studies have in fact further demonstrated the efficacy and safety of a 16-week treatment with anti-inflammatory doxycycline (40 mg once daily) in patients with rosacea [31]. This medication led to a significant reduction in inflammatory lesions [31]. Hence anti-inflammatory doxycycline (40 mg) applied once daily must be regarded to be a promising therapy strategy for papulopustular rosacea – besides topical therapies with metronidazole or azelaic acid. However, to our knowledge it is not known if tetracyclines, in particular doxycycline, are able to improve the symptom flushing, whereas topical application of selective α1-adrenergic receptor agonists like oxymetazoline seems to be successful in this regard [15]. This finding is in accordance with the belief that flushing may be due, at least partly, to an abnormal expression, function, distribution or responsiveness of α-adrenergic receptors [15].

**Tetracycline Derivatives, Especially Doxycycline, and Their Mode of Action**

**Inhibition of MMPs**

In the 1980s, Golub et al. [47] discovered a novel nonantimicrobial property of tetracyclines. They found that tetracyclines have the ability to inhibit the activity of interstitial MMPs from a variety of cells like neutrophils and macrophages and tissues such as skin [47, 48]. MMPs are zinc-dependent enzymes significantly involved in the remodeling of connective tissue. They are secreted by resident and inflammatory cells that collectively degrade most of the constituent macromolecules of the extracellular matrix. These enzymes with their subgroups of collagenases (MMP-1, MMP-8, MMP-13) and gelatinases (MMP-2, MMP-9) play an important role in many inflammatory diseases, wound healing, embryogenesis, tumor invasion and angiogenesis [30, 49]. Furthermore, MMPs contribute to cytokine (i.e. IL-1β)-induced vascular dysfunction as could be shown in vitro and in an in vivo model of acute inflammation [50] (fig. 1). Later it has been observed that tetracycline inhibition of MMPs differs between species, tissues and even cells from the same tissue [51]. Furthermore, it could be shown that the members of the tetracycline family differ in their potency to inhibit extracellular collagenase activity, with the semisynthetic drugs doxycycline and minocycline being more potent than tetracycline itself [48, 52].

In vitro and in vivo studies report that tetracycline derivatives are able to inhibit the activity of various MMPs playing a role in the breakdown of the extracellular matrix, including MMP-13 (collagenase-3), MMP-8 (collagenase-2), MMP-1 (collagenase-1), MMP-2 (gelatinase A), MMP-9 (gelatinase B) and MMP-12 (macro-
phage metalloelastase) [11, 31, 53, 54]. For some MMPs it has been shown that, in addition to inhibiting MMP activity, tetracycline derivatives like doxycycline may also reduce enzyme expression at the transcriptional level [55].

While the inhibitory effects of low-dose doxycycline on MMPs are described in detail in the context of the management of periodontitis [56–60], available data for skin diseases like acne or rosacea are relatively scanty. However, there are data indicating that MMP-9 can be inhibited by tetracycline derivatives as well probably due to reduction in the chemotaxis of neutrophils, which are known to store MMP-9 [30]. The inhibitory effect of doxycycline on MMP-9 levels could be approved by studies using an experimental dry-eye model in mice [61]. The studies of Kim et al. [62] showing that doxycycline inhibits the TGF-β1-induced production of MMP-9 in cultured corneal epithelial cells as well suggest that this finding might be relevant to the pathogenesis in ocular rosacea [49, 62]. More evidently, recent work even suggests that high levels of MMP-8 in the tear fluid are correlated with ocular rosacea and that low-dose doxycycline is able to lower the pathologically increased levels in these patients. Määtä et al. [63] actually found that the mean MMP-8 concentrations were significantly higher in patients with ocular rosacea (157 µg/ml) than in normal subjects (53 µg/ml) but decreased to 79 and 53 µg/ml in patients with ocular rosacea after 4 and 8 weeks of treatment with low-dose doxycycline, respectively (fig. 2). The reduction in MMP-8 levels was related to a relief in the patients’ subjective symptoms [63].

Up to now, doxycycline hyclate is the only drug whose properties to inhibit MMPs have sufficed for approval of clinical use [64], but the exact mode of action on the molecular level is still unknown. Recent work indicates that doxycycline does not directly inhibit MMPs or the synthesis/secretion of these proteases. Though orally administered doxycycline caused a disappearance of the MMPs indicative of disease progression in patients with superficial ocular diseases, especially rosacea, no doxycycline could be detected in their tear samples [65]. Thus, doxycycline seems to influence MMPs in an indirect way.

Inhibition of Phospholipase A2
Extracellular phospholipase A2 (PLA2) plays an important role in articular and extra-articular inflammatory processes [66]. The tetracyclines minocycline and, to a lesser extent, doxycycline have been shown to be inhibitory to both pancreatic and nonpancreatic PLA2 in vitro [66]. However, the doxycycline concentration needed for in vitro inhibition of the enzyme activity in serum from patients with acute necrotizing pancreatitis is higher than that achieved after intravenous injections in clinical use [67]. Thus, up to now the importance of PLA2 inhibition by doxycycline in vivo and especially in skin diseases like rosacea remains unclear, particularly with regard to the finding that in tears of patients with ocular rosacea and, more specifically, in patients with dry eyes...
the content of PLA2 of group IIA is significantly lower compared to normal controls [68].

**Downmodulation of Cytokines**

Inflammatory lesions from acne patients contain increased levels of proinflammatory cytokines like TNF-α and IL-1β postulated to be involved in the inflammatory cascade of acne [9] and triggering chemical responses like the release of certain MMPs [13]. There is evidence that tetracyclines at subantimicrobial doses reduce inflammation by their downregulating properties [36], especially with respect to TNF-α and IL-1β [69], IL-8 [70] and IL-10 [71]. Furthermore, low-dose doxycycline seems to be able to normalize lowered levels of cytokines necessary for repair and regeneration. In patients with severe generalized chronic periodontitis, subantimicrobial-dose doxycycline increases the levels of TGF-β1 in the gingival crevicular fluid and by this means contributes to the inhibition of connective tissue breakdown [72]. For rosacea no corresponding studies are available so far, but it is to be assumed that the described mechanisms are, at least partly, transferable to this disease as well.

**Inhibition of Cell Movement and Proliferation**

The migration of white blood cells is an early and important event in the process of inflammation. Data from the late 1970s and 1980s show that tetracyclines are able to interfere with neutrophil function [37], especially with neutrophil movement, at least in vitro [73]. Tetracyclines have also been found to be able to inhibit the mitogen-induced proliferative responses of human lymphocytes in vitro by blockage of blast formation, with doxycycline being the most potent inhibitor among 3 tested tetracycline analogues [37]. Gabler et al. [74] could show that the chelation of intracellular calcium, which, as a second messenger, is important for the regulation of cell movement, is involved in the mechanism of inhibition. Besides migration, tetracyclines are also able to inhibit neutrophil-mediated superoxide anion synthesis and degranulation, i.e. mechanisms which may also be involved in the inflammatory process [75]. Lately, Gabler and Tsukuda [76] found that doxycycline also exerts a slight inhibitory effect on neutrophil adherence to surfaces coated with differing proteins, which interestingly could only be observed at low drug concentrations of doxycycline, while tetracycline inhibited leukocyte adherence in a dose-related manner.

**Inhibition of Granuloma Formation**

Granulomatous inflammation is a common component of many diseases, including rosacea. Tetracyclines have been shown to inhibit granuloma formation of human peripheral blood mononuclear cells incubated with dextrin beads [77]. In this in vitro system doxycycline was proven to have a 10-fold stronger inhibitory activity than the parent drug tetracycline. Protein kinase C may be involved in the described mechanism of inhibition because tetracyclines caused a dose-dependent inhibition of protein kinase C in the same order of relative potency as was found for the inhibition of granuloma formation [77].

**Inhibition of ROS**

Evidence has been accumulating that ROS released by inflammatory cells such as neutrophils [12] are involved in the pathogenesis of rosacea. Patients with rosacea have higher ROS levels than healthy controls [78]. Furthermore, markers of the antioxidant defense system are inversely correlated to the clinical manifestations of rosacea. This means that in patients with mild rosacea (stage I or II) the superoxide dismutase activity was higher than in healthy controls while the malondialdehyde level (a biomarker for oxidative stress [79]) did not differ from controls, whereas in the severe involvement group (rosacea stage III) the superoxide dismutase activity was lower than in the control group coupled to an increased level of malondialdehyde [14]. These findings suggest that in mild rosacea the antioxidant defense system is activated in order to keep the ROS levels constant. In severer disease, the capacity of the antioxidant system is exhausted, leading to high levels of ROS. This belief is supported by recent data showing a higher ferritin expression in the skin, higher serum peroxide levels and significantly lowered total antioxidative potential serum levels in patients with rosacea compared with healthy control subjects, indicating the onset of systemic oxidative stress in patients with rosacea [80]. These findings support the ‘antioxidant system defect hypothesis’ in rosacea patients, i.e. a reduced capacity to counter the negative effects of ROS, thus experiencing an increased inflammatory response [13, 14]. This may also explain the pathogenetic association between rosacea and photodamage, since long-term sun exposure is known to cause an increased generation of ROS, which, in turn, subsequently activate MMPs and in this way trigger the inflammation pathway [13, 31].

In vitro studies suggest that tetracyclines, especially doxycycline, show antioxidant effects by reducing ROS [30, 60]. In vitro data propose that the antioxidant effect of these drugs does not originate from their capability to directly scavenge ROS but from their influence on white blood cells [81]. However, the exact mechanism of action
of tetracyclines towards white blood cells, especially neutrophils, is still unknown [12, 82]. The tetracycline-induced reduction in ROS activity seems to be linked to a decreased degradation of extracellular matrix associated with a reduced activation of pro-MMPs [31]. Thus, the antioxidant activity of tetracyclines may also benefit other mechanisms of inflammation.

**Inhibition of NO**

The overproduction of NO has been implicated in the pathogenesis of various inflammatory diseases [83]. NO secreted by endothelial cells and keratinocytes in response to UVA and UVB radiation [84] is thought to incite the symptoms of rosacea as well [13]. NO seems to be involved in vascular changes, i.e. vasodilation, which, in the case of rosacea, may contribute to increased vessel permeability, erythema, edema and telangiectatic symptoms [13]. The increase in NO in response to UVA and UVB irradiation [84] again refers to the widely accepted relationship between sun exposure and the pathogenesis of rosacea.

Tetracyclines have been shown to inhibit the expression of nitric synthases under ex vivo conditions, with doxycycline being at least as effective as minocycline [83]. Furthermore, doxycycline has been shown to be involved in the posttranscriptional regulation of inducible NO synthetase mRNA in murine macrophages [85]. All these preliminary results suggest that tetracyclines, especially doxycycline, may have beneficial effects in the treatment of inflammatory diseases where excess NO has been implicated in the pathophysiology, as also seems to be the case with rosacea.

**Inhibition of Angiogenesis**

Angiogenesis seems to be involved in the pathogenesis of rosacea [19, 86] and to be linked to MMP activity [36]. In patients with rosacea, significantly increased dermal expression of the potent angiogenesis factor vascular endothelial growth factor in lesional versus nonlesional skin (88.9 vs. 55.6%, respectively) was observed. Furthermore, more microvessels were observed in lesional compared to clinically nonlesional skin, and a high microvessel density was found to be correlated with granuloma formation in the skin [19]. There was also a correlation between high vascular density and the presence of ocular manifestations [19].

Up to now, no study is available showing a direct or indirect antiangiogenic effect of tetracyclines in the pathogenesis of rosacea. Yet in a mouse model, doxycycline has been found active in suppressing MMP-associated central nervous system angiogenesis [49, 87]. In this model, doxycycline turned out to be a potent inhibitor of angiogenesis induced by vascular endothelial growth factor by decreasing the cerebral MMP-9 activity. The decrease in MMP-9 was associated with a reduced microvessel count [87]. More recently, it has been shown that doxycycline attains consistent antiangiogenic effects by inhibiting the migration of smooth-muscle cells playing an important role during angiogenesis and vascular remodeling [88]. There is good evidence that inhibition of smooth-muscle cell migration is caused by the doxycycline-induced upregulation of the MMP inhibitor tissue inhibitor of metalloproteinase-1 [88].

**Influence on D. folliculorum**

The saprophytic mite *D. folliculorum* may play a pathogenic role in papulopustular rosacea [17–21]. Increased density of *D. folliculorum* may be involved in the pathogenesis of rosacea by supporting inflammation, mechanical blockage of follicles or by acting as vectors for microorganisms [17, 22], while other authors favour the concept that increased mite density is the consequence of a previous treatment with topical steroids [23]. Up to now, to our knowledge no study showing a relevant direct action of tetracyclines on the density of *D. folliculorum* is available.

**Conclusion**

It is highly probable that rosacea is of inflammatory nature. Inflammatory processes involved in the pathogenesis of the disease concomitantly contribute to the common symptoms such as inflammatory lesions in the stricter sense, erythema, telangiectasia, phymatous changes and ocular symptoms. Evidence has been accumulating that tetracycline derivatives like doxycycline successfully used in the treatment of rosacea inhibit inflammatory pathways in skin diseases like acne and rosacea by various modes of action. Although data for acne or rosacea are relatively scanty, the following modes of action of tetracyclines seem to be most relevant to an effective treatment of these skin diseases: inhibition of MMPs, downmodulation of cytokines, inhibition of cell movement and proliferation, granuloma formation, ROS, NO and angiogenesis, whereas inhibition of PLA2 does not seem to matter greatly. The role of the saprophytic mite *D. folliculorum* remains to be clarified. Nevertheless, future studies will have to show how tetracyclines work in rosacea treatment in detail.
References


Tetracycline Actions Relevant to Rosacea Treatment